GlassScriptPhysician profile
Neevon C Esmaili
NPI 1801051248
$544.45
in general payments reported to CMS, 2019-2025
10 companies · $27.85 in 2025
The $27.85 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2021: $55.32 · 2022: $33.44 · 2023: $137 · 2024: $58.50 · 2025: $27.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $223.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $174.36 | 2019 | |
| Janssen Pharmaceuticals, INC | $90.98 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.35 | 2024-2025 | Caplyta |
| Abbvie INC. | $55.40 | 2023 | |
| Supernus Pharmaceuticals, INC. | $36.40 | 2021 | |
| Lundbeck LLC | $33.36 | 2023 | Rexulti |
| Alkermes, INC. | $26.00 | 2024 | Lybalvi |
| Axsome Therapeutics, INC. | $24.51 | 2023 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $24.17 | 2023 | Abilify Mycite |
| Adlon Therapeutics L.P. | $18.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neevon Esmaili listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.